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Abstract
17b-estradiol (E2), the most potent estrogen in humans, known to be involved in the development and progession of
estrogen-dependent diseases (EDD) like breast cancer and endometriosis. 17b-HSD1, which catalyses the reduction of the
weak estrogen estrone (E1) to E2, is often overexpressed in breast cancer and endometriotic tissues. An inhibition of 17b-
HSD1 could selectively reduce the local E2-level thus allowing for a novel, targeted approach in the treatment of EDD.
Continuing our search for new nonsteroidal 17b-HSD1 inhibitors, a novel pharmacophore model was derived from
crystallographic data and used for the virtual screening of a small library of compounds. Subsequent experimental
verification of the virtual hits led to the identification of the moderately active compound 5. Rigidification and further
structure modifications resulted in the discovery of a novel class of 17b-HSD1 inhibitors bearing a benzothiazole-scaffold
linked to a phenyl ring via keto- or amide-bridge. Their putative binding modes were investigated by correlating their
biological data with features of the pharmacophore model. The most active keto-derivative 6 shows IC50-values in the
nanomolar range for the transformation of E1 to E2 by 17b-HSD1, reasonable selectivity against 17b-HSD2 but pronounced
affinity to the estrogen receptors (ERs). On the other hand, the best amide-derivative 21 shows only medium 17b-HSD1
inhibitory activity at the target enzyme as well as fair selectivity against 17b-HSD2 and ERs. The compounds 6 and 21 can be
regarded as first benzothiazole-type 17b-HSD1 inhibitors for the development of potential therapeutics.
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Introduction
Estrogens are important steroidal hormones which exert
different physiological functions. The main beneficial effects
include their role in programming the breast and uterus for
sexual reproduction [1], controlling cholesterol production in ways
that limit the build-up of plaque in the coronary arteries [2], and
preserving bone strength by helping to maintain the proper
balance between bone build-up and breakdown [3–4]. Among
female sex hormones, 17b-estradiol (E2) is the most potent
estrogen carrying out its action either via transactivation of
estrogen receptors (ERs) [5] or by stimulating nongenomic effects
via the MAPK (mitogen-activated protein kinase) signaling
pathway [6]. In addition to its important beneficial effects,
however, E2 can also cause serious problems arising from its
ability to promote the cell proliferation in breast and uterus.
Although this is one of the normal functions of estrogen in the
body, it can also increase the risk of estrogen dependent diseases
(EDD), like breast cancer, endometriosis and endometrial
hyperplasia [7–10]. Suppression of estrogenic effects is conse-
quently a major therapeutic approach. This is proved by routine
clinic use of different endocrine therapies, for instance with GnRH
analogues, SERMs (selective estrogen receptor modulators),
antiestrogens, and aromatase inhibitors [11–13] for the prevention
as well as the adjuvant treatment of breast cancer. However, all
these therapeutics systemically lower estrogen hormone action and
may cause significant side effects such as osteoporosis, thrombosis,
stroke and endometrial cancer [14–16]. Thus, a new approach,
which aims at affecting predominantly the intracellular E2
production in the diseased tissues (intracrine approach), would
consequently be a very beneficial improvement for the treatment
of EDD. Such a therapeutic strategy has already been shown to be
effective in androgen dependent diseases like benign prostate
hyperplasia by using 5a-reductase inhibitors [17–21].
17b-HSD1, which is responsible for the intracellular NAD(P)H-
dependent conversion of the weak estrone E1 into the highly potent
estrogen E2, was found overexpressed at mRNA level in breast
cancer cells [22–24] and endometriosis [25]. Inhibition of this
enzyme is therefore regarded as a novel intracrine strategy in EDD
treatment with the prospect of avoiding the systemic side effects of
the existing endocrine therapies. Although to date no candidate has
entered clinical trials, the ability of 17b-HSD1 inhibitors to reduce
the E1 induced tumor growth has been shown using different animal
models, indicating that the 17b-HSD1 enzyme isa suitable target for
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demonstrated by Day et al. [28], Laplante et al. [29] and Kruchten
et al. [30] using in vitro proliferation assays.
In order not to counteract the therapeutic efficacy of 17b-HSD1
inhibitors it is important that the compounds are selective against
17b-hydroxysteroid dehydrogenase type 2 (17b-HSD2). This
enzyme catalyses the reverse reaction (oxidation of E2 to E1),
thus playing a protective role against enhanced E2 formation in
the diseased estrogen dependent tissues. Potent and selective 17b-
HSD2 inhibitors for the treatment of osteoporosis were recently
reported [31–32]. Additionally, to avoid intrinsic estrogenic and
systemic effects, the inhibitors should not show affinity to the
estrogen receptors a and b.
Several classes of 17b-HSD1 inhibitors have been described in
the last years [33–47], most of them having a steroidal structure.
During the past decade, our group reported on four different
classes of nonsteroidal 17b-HSD1 inhibitors [48–58]. Compounds
1–4 (Figure 1) exhibit IC50 values toward 17b-HSD1 in the
nanomolar range and high selectivity against 17b-HSD2 and the
ERs in our biological screening system [59].
In our search for new nonsteroidal 17b-HSD1 inhibitors that are
structurally different from those previously described, an in silico
screening of an in-house compound library was performed using a
pharmacophore model derived from crystallographic data. Upon
experimental validation, a virtual hit could be identified as a
moderately active inhibitor of 17b-HSD1 (Table S1, compound 5);
structural optimization led to the discovery of benzothiazoles as
novel, potent inhibitors of the target enzyme with good biological
activity in vitro. Further computational studies were performed to
better understand the favourable interactions achieved by these
inhibitors in the active site.
Materials and Methods
Pharmacophore model
Although up to now more than twenty crystallographic
structures of human 17b-HSD1 are available in the Protein Data
Bank (PDB) as apoform, binary or ternary complex (with steroidal
ligand and/or cosubstrate), X-ray based information about
protein-ligand interactions of the enzyme with nonsteroidal
inhibitors is not available. Furthermore, the steroidal binding
pocket in these crystal structures displays differences in terms of
size and geometry due to a pronounced flexibility of some parts of
its surroundings [60]. Therefore, a simple virtual screening
strategy such as random selection of one crystal structure to
perform docking studies was considered unsuitable to the search
for new hits. As in silico screening tool, a new pharmacophore
model for 17b-HSD1, based on cocrystallized ligands and with
some additional protein structure information, was built and a
ligand-based approach was followed instead.
Five diverse 17b-HSD1 crystal structures (PDB-ID: 1a27, 1equ,
1dht, 1i5r, 3hb5) [61–65] were superimposed (backbone root
mean square deviation (RMSD) of 0.7 A ˚) and the cocrystallized
steroidal ligands E2, EQI, DHT, HYC and E2B, respectively,
(Figure 2) were used to build the pharmacophore model using the
Molecular Operating Environment (MOE; www.chemcomp.com)
software.
The five crystal structures were chosen to cover most of the
chemical space occupied by their 17b-HSD1 ligands, and both the
presence of the cosubstrate (NADP
+/NADPH) and a good
resolution were considered important for their selection as the
pharmacophore model should integrate both ligand- and protein-
derived information, gained from the analysis of different crystal
structures.
Superimposition of the mentioned 3D complexes (ligands and
proteins) enabled us to define the pharmacophore features of both
the ligands and of the constant regions of the protein, involved in
ligand-protein interaction. While the selection of the ligand-
derived features was focused on the slightly different chemical
properties of substrates and inhibitors, the protein-derived features
were chosen considering ‘‘rigid’’ active site residues (all atom
RMSD for all crystal structures,0.5 A ˚) as well as amino acids
important for the enzymatic activity. Furthermore, the flexible
bFaG’-loop (residues 187–196) [60] lining the active site was
excluded, whereas additional donor/acceptor features of the
cofactor (NADP
+) were considered.
Thus, on the ligand side the pharmacophore model (Figure 3)
consists of five hydrophobic/aromatic features HY1-HY5 (four
from steroid scaffold and one from E2B/HYC, respectively), one
aromatic ring projection P5 (associated to HY5; used to direct the
ligand placement in the pharmacophore screen), three H-bond
acceptor-and-donor AD1-AD3 (two from the steroid scaffold and
one from E2B) and one H-bond donor D4 (corresponding to the
NH2 of the amide in E2B).
Nine acceptor (A) or donor (D) feature projections were derived
from the protein and were used to direct the ligand orientation in
the pharmacophore screening (projections indicate putative
protein binding partners; the number indicate the the ligand
feature, while the small letters a and b describe the inverse H-
bonding properties of residues involved in a common network, e.g.
A1a is a donor and D1b is an acceptor, and both interact with
AD1): A1a - His221, D1b - Glu282, AD2a - Ser142, AD2b -
Tyr155, A3a - Leu96, D4a - Asn152, D4b - Leu95, AD5a -
Ser222, AD5b - Tyr218. In addition, four features were also
retained from the cofactor NADP(H): A6b and D6a from the
amide moiety, HY6 as aromatic ring projection from the
nicotinamide ring (potential interaction site of the ligand with
Tyr155 and cofactor), and D7 as acceptor projection (phosphate
group of the cofactor). More geometric properties of the
pharmacophore are listed in Table S2.
Figure 1. Nonsteroidal 17b-HSD1 inhibitors published by our group.
doi:10.1371/journal.pone.0029252.g001
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PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29252Figure 2. Steroidal ligands co-crystallized with 17b-HSD1. The five steroidal ligands cocrystalized with 17b-HSD1s that were used to build the
pharmacophore model. Structural information was taken from the protein data bank(PDB-ID: 1a27, 1equ, 1dht, 1i5r, and 3hb5, respectively).
doi:10.1371/journal.pone.0029252.g002
Figure 3. Pharmacophore model. The pharmacophoric features derived from the ligands are rendered as dotted spheres and are color-coded:
dark orange for aromatic ring and aromatic ring projection (HY1 and HY5), green for hydrophobic regions (HY2-HY4) and magenta for acceptor
and donor atom features (AD1-AD3 and D4). The identified aromatic ring projection HY6 as well as the donor projection feature D7 is not
exploited by steroidal inhibitors. The protein-derived acceptor or donor features (A1a, D1b, AD2a, AD2b, A3a, D4a, D4b, AD5a, AD5b, D6a and
A6b) and the aromatic ring projection P5 are depicted as yellow, meshed spheres.
doi:10.1371/journal.pone.0029252.g003
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to screen a small in house library (approximately forty thiazole
derivatives with molecular weight in the range of 150–350; structures
are given in Table S3) and the virtual hits were experimentally
validated. A partial match strategy was adopted for the screening, in
which the molecules are left free to be placed into the pharmacophore
and only virtual hits are considered that cover at least six features.
Chemistry
For the sake of clarity, IUPAC nomenclature is not strictly
followed except for the experimental section (see File S1) where the
correct IUPAC names are given.
The synthesis of the thiazolyl derivative 5 was performed as
shown in Figure 4 starting from the commercially available 2-(4-
methyl-1,3-thiazol-5-yl)ethanol and 3-hydroxybenzaldehyde.
To avoid side reactions due to the presence of the free hydroxy
groups, they were reacted with tert-butyldimethylsilyl chloride and
imidazole in DMF at room temperature overnight [66] to afford
5iiia and 5iiib, respectively. Then nucleophilic addition [67] of
5iiia (after in situ lithiation in the 2-position) to 5iiib in THF at
215uC for 90 minutes yielded the secondary alcohol 5ii. The
latter was oxidized to the carbonyl derivative 5i using stabilized 2-
iodoxybenzoic acid (SIBX) as oxidative reagent in THF at 60uC
[68] prior to the removal of both silyl protecting groups under
mild basic conditions (TBAF in THF at room temperature for
2 hours) [69] to afford compound 5.
The benzothiazolyl derivatives 6–11 and 13–18 were synthe-
sized as shown in Figure 5.
The commercially available 6-methoxy-benzothiazol-2-yl amine
was reduced to 6iii in the first step via a previously described
diazotation and subsequent reductive elimination of nitrogen [70]
as follows: 6-methoxy-benzothiazol-2-yl amine was first dissolved
in 85% phosphoric acid under gentle heating and then cooled to
210uC. Then, an aqueous solution of NaNO2 was slowly added to
yield the diazonium salt. The latter was subsequently transformed
in situ to 6iii by adding the reaction mixture to chilled 50%
aqueous phosphonic acid (0uC) and allowing the temperature to
rise to room temperature overnight. The thus obtained interme-
diate 6iii was lithiated in the 2-position and subjected to
nucleophilic addition to 3-methoxybenzaldehyde or 4-methox-
ybenzaldehyde, respectively, in THF at 215uC for 90 minutes, to
afford the secondary alcohols 6ii and 9ii. The same method was
used for the synthesis of 12ii, starting from the commercially
available benzothiazole and 3-methoxybenzaldehyde, as well as
for the preparation of the amides 15i and 17i, starting from 6iii
and 2-methoxybenzoisocyanate or 3-methoxybenzoisocyanate,
respectively. The secondary alcohols 6ii, 9ii and 12ii were
oxidized to the corresponding carbonyl derivatives 6i, 12i and
13i. The cleavage of the methoxy groups of 9ii with BF3S(CH3)2
in anhydrous CH2Cl2 at room temperature for 20 hours [49] took
place with concomitant formation of the thioether derivative 9.
The reduction of 9ii using trimethyl silyl chloride and NaI in
acetonitrile [71] led to the formation of the desired compound 11i
and an additional product (10), lacking one of the two methoxy
groups . The reaction of 6i with BF3S(CH3)2 led to the formation
of the desired compound 6 and two additional reduced products (7
and 8). The ether cleavage of the methoxy groups of compounds
11i–13i was carried out by using pyridinium hydrochloride at
220uC for 4 hours [49] to afford compounds 11–14. This latter
method proved to be very efficient for ketones. The cleavage of the
methoxy groups of 15i and 17i with BF3S(CH3)2 gave access to
the amide derivatives 15–18. For some substrates the ether
cleavage could not be driven to completeness. In those cases the
formation of both monomethoxy derivatives was observed but
only one could be isolated in the purification step.
The benzamides (19–21), benzenesulfonamide (22), urea (23),
thiourea (24) and acetamide (25) derivatives were afforded in a
common two-steps synthetic pattern (Figure 6).
Compounds 19i and 21i–25i were synthesised via amide
coupling [72] starting from the commercially available 6-
methoxybenzothiazol-2-ylamine and 4-methoxybenzoyl chloride,
3-methoxybenzoyl chloride, 3-methoxysulfonyl chloride, 3-meth-
oxybenzoisocyanate, 3-methoxybenzoisothiocyanate and 3-meth-
oxyphenyl acetyl chloride, respectively. The ether cleavage of the
methoxy groups was carried out to yield compounds 19–25.
Similarly to the ether cleavage of the amides, BF3S(CH3)2 was
successfully applied in the case of retro amides (19–21). BBr3 was
instead used for the synthesis of compounds 22–25.
Fully described reactions conditions, NMR spectroscopic data
and purity data for the final compounds using LC/MS are
available in File S1.
Biological assays
1) 17b-HSD1 cell free assay. In the cell free assay, the
placental cytosolic enzyme was used. Tritiated E1 (final
concentration: 500 nM) was incubated with 17b-HSD1, NADH
(500 mM), and inhibitor as previously described [59]. After high
performance liquid chromatography (HPLC) separation of
substrate and product, the amount of labeled E2 formed was
quantified. The hybrid inhibitor (EM-1745) evaluated using
recombinant protein and NADPH as cosubstrate in a cell free
assay as described by Poirier et al. [64] was used as external
reference and gave similar values as described (IC50=52 nM).
Compounds showing less than 10% inhibition at 1 mM were
considered to be inactive. IC50 values were determined for
compounds showing more than 70% inhibition at 1 mM.
Compound 2 (Figure 1), identified in a previous study [51], was
used as internal reference (IC50=8 nM).
Figure 4. Synthesis of compound 5. Reagents and conditions: (a) TBDMSiCl, imidazole, DMF, rt, 20 h; (b) 1) nBuLi, anhydrous THF, 270uC, 1 h; 2)
5iib, anhydrous THF, 215uC, 90 min; (c) SIBX, anhydrous THF, 0uCt o6 0 uC, 20 h; (d) TBAF, THF, rt, 2 h.
doi:10.1371/journal.pone.0029252.g004
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determined for compounds showing 17b-HSD1 inhibitory
activity of 70% at 1 mM using an established assay [59]
similar to the 17b-HSD1 test and a selectivity factor
(SF=IC50(17b-HSD2)/IC50(17b-HSD1)) was determined.
Placental microsomal 17b-HSD2 was incubated with tritiated
E2 (final concentration: 500 nM) in the presence of NAD
+
(1500 mM) and inhibitor. Separation and quantification of
labeled substrate (E2) and product (E1) was performed by
HPLC using radiodetection.
Figure 6. Synthesis of compounds 19–25. Reagents and conditions: (a) pyridine, 100uC, 20 h, for 19i: p-methoxybenzoylchloride, for 21i: m-
methoxybenzoylchloride, for 22i: m-methoxyphenylsulfochloride, for compound 23i: m-methoxybenzoisocyanate, for 24i: m-methoxybenzoi-
sothiocyanate, for compound 25i: m-methoxybenzylchloride; (b) for 19–21,B F 3S(CH3)2, anhydrous CH2Cl2, rt, 20 h; for 22–25, BBr3,C H 2Cl2, 278uC
to rt, 20 h.
doi:10.1371/journal.pone.0029252.g006
Figure 5. Synthesis of compounds 6–18. Reagents and conditions: (a) 1) NaNO2,H 3PO4 (85%), 210uC, 20 min, 2) H3PO2,H 3PO4 (85%), 210uCt o
rt, 20 h; (b) 1) nBuLi, anhydrous THF, 270uCt o220uC, 1 h, 2) for 6ii and 12ii: m-methoxybenzaldehyde, for 9ii: p-methoxybenzaldehyde, for 15i: o-
methoxybenzoisocyanate, for 17i: m-methoxybenzoisocyanate, anhydrous THF, 215uC, 90 min; (c) for 6i, 12i and 13i, SIBX, anhydrous THF, 0uCt o
60uC, 20 h; for 10 and 11i: TMSiCl, NaI, CH3CN, reflux, 20 h; (d) for 6–9 and 15–18:B F 3S(CH3)2, anhydrous CH2Cl2, rt, 20 h; for compounds 11–14,
pyridinium hydrochloride, 220uC, 4 h.
doi:10.1371/journal.pone.0029252.g005
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ERs of the most interesting compounds of this study were
determined using recombinant human protein (0.25 pmol of ERa
or ERb, respectively) in a previously described competition assay
[59] applying [
3H]E2 (10 nM) and hydroxyapatite.
4) Intracellular potency. The intracellular potency of the
most selective compound to inhibit E2 formation was evaluated as
previously described [59] using the T47-D [30] cell line (obtained
from ECACC, Salisbury) that expresses 17b-HSD1 and - to a
much lesser extent -17b-HSD2 [73].
Fully described procedures regarding the biological assays are
available as File S1.
Results
1) Hit identification and optimization
[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-2-yl](3-hydroxyphenyl)-
methanone) (5) resulted to be the most potent hit, exploiting the
following six features: HY2-HY5, AD2 and D4 (Figure 7A).
Applying the strategy of rigidification (decrease conformational
degrees of freedom), compound 6 was designed which is
characterized by a ring closure of the flexible hydroxyethyl chain
of compound 5, leading to a benzothiazole moiety linked via a
carbonyl bridge in the 2 position to 3-hydroxy-phenyl ring (see
Figure 8).
Interestingly, in a subsequent docking experiment, also
compound 6, the rigidified analogue of 5, was found to match
six pharmacophoric features (Figure 7B). Its superimposition with
equilin, one of the steroidal ligands used to build the pharmaco-
phore model, shows that the phenyl ring of the benzothiazole
moiety can mimic the steroidal B ring (see Figure S1).
The carbonyl bridge between the two aromatic rings in
compound 6 bearing a sp
2 trigonal geometry allows for electronic
delocalization (conjugation), and the oxygen atom may accept two
H-bonds. To investigate the influence of these features on the 17b-
HSD1 inhibitory activity, compounds 7–11 (Table S1), bearing a
sp
3 tetrahedral bridge, were synthesized.
The carbonyl bridge was also replaced by more spacious
functional groups, such as amide (i.e. 18), retro amide (i.e. 21),
sulfonamide (22), urea (23), thiourea (24) and benzyl amide (25)t o
inquire whether such a modification could allow the compounds to
interact with different or additional regions of the binding cleft.
2) Activity: Inhibition of human 17b-HSD1
The inhibition values of the test compounds are shown in Table
S1. The rigidified benzothiazole derivative 6 was far more potent
towards the target enzyme (91% at 1 mM, IC50=44 nM) than 5
(34% at 1 mM) and thus turned out to be a very promising scaffold
taking into account also its low molecular weight (271 g/mol).
The inhibitory potency of the compounds is strongly dependent
on length and type of the bridge connecting the aromatic moieties.
The replacement of the flat sp
2 bridge (methanone in compound
6) by a tetrahedral one, as present in the alcohol 7, its methyl ether
8, the corresponding thioether 9, and the methylene compound
11, turned out to be deleterious for the inhibitory activity at the
target enzyme. Compounds 7–9 showed activities of 28%, 13%
and 7%, respectively, at 1 mM concentration. The loss of potency
observed for these compounds as well as for compounds 10 and 11
seems to be induced by the bridge geometry and not by the H-
bonding properties, since a hydroxy- (acceptor and donor), a
methoxymethyl- (acceptor only), and a methylene-group (neither
acceptor nor donor) all led to a decrease in activity, compared to
the carbonyl group.
As the keto bridge appeared to be the most appropriate
functionality, it was maintained as starting point for further
structural modifications. Compound 12, without hydroxy group in
the 6-position of the benzothiazole moiety, was designed to
evaluate the importance of this functional group (6i) and showed 8
fold lower inhibitory activity than 6 (see Table S1). Furthermore,
to investigate whether either a methoxy or a hydroxy group in
para-positionon of the phenyl moiety of compound 6 could exploit
the pharmacophoric feature AD3 (see Figure 7B) compounds 13
and 14 were synthesized. The lower inhibitory activity of the para-
methoxy derivative 13 (27% at 1 mM) compared to that of the the
Figure 7. Compounds 5 (A) and 6 (B) mapped to the pharmacophore model.
doi:10.1371/journal.pone.0029252.g007
Figure 8. Rigidification strategy.
doi:10.1371/journal.pone.0029252.g008
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the importance of an H-bonding donor in this position; there is,
however, a decrease of activity when the hydroxy group is shifted
from the meta- (compound 6,I C 50=44 nM) to the para-position
(compound 14).
Compounds with two bridging atoms between the hydroxyphe-
nyl- and the hydroxybenzothiazole moieties, like amide 18,
retroamide 21, and sulfonamide 22, were also synthesized. In
the amide series, both the H-bonding properties as well as the sp
2
geometry turned out to be discriminating factors for 17b-HSD1
inhibitory activity. The introduction of an amide bridge in the
place of the keto function results in a significantly decreased
inhibitory potency (compound 18: 40% inhibition at 1 mM vs
compound 6:I C 50=44 nM). This is even more pronounced in the
case of the sulfonamide derivative 22 which is inactive.
Replacement with retro amide (leading to compound 21),
however, gives only a slight decrease of inhibitory activity (21:
IC50=243 nM vs 6:I C 50=44 nM).
Changing the hydroxy substitution pattern (16 and 20) as well
as replacement of –OH with methoxy (15, 17 and 19) are
modifications detrimental for activity, independent on the nature
of the bridge (amide or retroamide).
The extension of the bridge to three units resulted in the
inactive urea 23 and benzylamide 25. Interestingly the thiourea
24 showed a moderate inhibitory activity.
3) Selectivity: Inhibition of 17b-HSD2 and affinities to the
estrogen receptors a and b
In order to gain insight into the selectivity of the most active
compounds, inhibition of 17b-HSD2 and the relative binding
affinities to the estrogen receptors a and b were determined. Since
17b-HSD2 catalyzes the inactivation of E2 into E1, inhibitory
activity toward this enzyme must be avoided. IC50 values and
selectivity factors are presented in Table S4.
Among the series bearing the keto bridge, compound 6 showed
the best selectivity factor (24 fold more active on 17b-HSD1 than
17b-HSD2). The absence of hydroxy on the benzothiazole (12)o r
moving the meta hydroxyl group of 6 to the para-position
(compound 14) leads to a drop in selectivity. Furthermore,
compound 21, bearing the retro amide bridge, shows a higher
selectivity factor (SF=38) than compound 18 (amide bridge,
SF=3) as well as compound 6 (carbonyl bridge, SF=24).
The ER binding affinities of the most interesting compounds of
this study (6 and 21) are shown in Table 1.
Compound 6 displays considerable affinities to both estrogen
receptors, whereas compound 21 shows marginal affinities (RBA
lower than 0.1% for ERa and lower than 0.001% for ERb).
4) Further biological evaluation
The ability of 21 to inhibit intracellular E2 formation was
evaluated. Incubation of T47-D cells with the compound in the
presence of labeled E1 resulted in a strong reduction of E2
formation within the cells (IC50=245 nM).
5) Binding mode analysis and SAR
In order to rationalize the influence of the different bridges in
this new set of 17b-HSD1 inhibitors, and to investigate their
potential binding modes, all tested compounds were docked in the
pharmacophore model.
The carbonyl compound 6 matches six pharmacophore features
(HY2-HY5, AD2 and D4), but it does not exploit the feature
HY1, which corresponds to the steroidal A-ring moiety (see
Figure 9A).
The retroamide 21 was found in a different orientation in the
pharmacophore with respect to 6, without occupying the feature
HY6. The compound may adopt two preferred isomeric forms (cis
and trans) which cannot be separated at room temperature because
they interconvert readily. The energetically more favorable [74]
linear (trans) isomer exploits the pharmacophoric features HY1-
HY4 and AD1. In addition, the hydroxy group of the
benzothiazole moiety is situated in close proximity to the aromatic
features HY5 and HY6, as depicted in Figure 9B. The cis isomer,
on the other hand, cannot match the required six features. Binding
of 21 in the trans-form may thus be assumed. Interestingly, the
retro amide bridge exploits the pharmacophoric feature HY2,
which in the case of compound 6 is exploited by the benzothiazole
phenyl ring. These data suggest very different binding modes for
the two compounds.
To better understand the favourable interactions established by
compounds 6 and 21 in the five different crystal structures used to
build up the pharmacophore model, a thorough analysis of the
respective surrounding residues was performed. For this purpose,
also the flexible amino acid residues, formerly excluded from the
pharmacophore generation process, were considered. The cocrys-
tallized steroidal ligands were replaced by either 6 or 21 (via the
pharmacophore) and the resultant complexes were optimized with
the ligX module of MOE. This module optimizes the protein-
ligand complex by first adjusting the protonation state of the
residues, tethering the active site heavy atoms and, finally, energy
minimizing the complex. The results highlighting the interactions
between our 17b-HSD1 inhibitors and the five crystal structures
are shown in Table 2.
For compound 6 five hydrogen bond interactions could be
observed: between its meta hydroxy group of the phenyl ring and
Asn152 (dO-O=2.45–2.97 A ˚ and dO-N=2.49–2.55 A ˚), between
the carbonyl oxygen of the bridge and both Ser142 and Tyr155
(dO-O=3.26–3.70 A ˚ and dO-O=3.71–3.90 A ˚), and between the
hydroxy group of the benzothiazol and His221 (dO-N=3.13–
3.33 A ˚). In addition, a cation-p interaction between the phenyl
ring of benzothiazole and Arg258 (dN-centroid=4.89 A ˚) as well as a
p-p interaction between the phenyl ring and Tyr155 (dcentroid-
centroid=3.98–6.71 A ˚) were found.
For compound 21 also five hydrogen bond interactions were
identified: between the meta hydroxy group of the phenyl ring and
both His221 and Glu282 (dO-N=2.45–2.65 A ˚ and dO-O=2.43–
2.52 A ˚, respectively), between the carbonyl oxygen of the amide
bridge and Tyr218 (dO-O 3.82 A ˚), and between the hydroxy group
of the benzothiazole and Tyr155 (dO-O=2.75–3.13 A ˚). Again, a
cation-p interaction between the phenyl ring and Arg258 was
found (dN-centroid=4.34 A ˚).
It is noteworthy that only the interactions with Tyr155 (p-p
stacking for 6 and hydrogen bond for 21) could be observed for all
Table 1. Binding affinities for the human estrogen receptors
a and b.
RBA
a (%)
Compound ERa
b ERb
b
6 1,RBA,10 0.1,RBA,1
21 0.01,RBA,0.1 RBA,0.001
aRBA (relative binding affinity). E2: 100%, mean values of three determinations,
standard deviations less than 10%.
bHuman recombinant protein, incubation with 10 nM [
3H]E2 and inhibitor for
1h .
doi:10.1371/journal.pone.0029252.t001
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whereas all the other were present depending on which crystal
structure was used. This further substantiated the importance of
Tyr155 for the stabilization of a ligand.
The differences in inhibitory activity between 6
(IC50=44nM)and21 (IC50=243 nM) could not be thoroughly
explained by considering only the hydrogen bonds, since only in
3hb5 and 1a27 more interactions were found for 6 compared to
21.O nt h ec o n t r a r y ,t h ep-p stacking interaction of 6 with
Tyr155, missing for 21, as well as the cation-p (charge transfer)
interaction between Arg258 and the phenyl ring of benzothia-
zole seem to be particularly important for the 17b-HSD1
inhibition. Compound 21 was found to be involved only in p-
stacking with Arg258, and no H-bond interactions with Ser142
were found in any of the complexes (exemplificative shown for
1equ, Figures 10 and 11).
In addition, the interactions between the hydroxy group in HY1
of compound 6 and His221, as found in different crystal structures
(1equ and 1i5r), is in agreement with the postulated binding mode.
Summarizing, the two best inhibitors (6 and 21) here described
bind very differently: they are flipped horizontally by 180u and the
planes of their benzothiazole moieties form an angle of 90u.
Figure 9. Pharmacophoric features exploited by 6 and 21. Six for compound 6 (showed in A) and five for compound 21 (showed in B).
doi:10.1371/journal.pone.0029252.g009
Table 2. Interactions found in the complexes between 6, 21 and the five 17b-HSD1 crystal structures used to build up the
pharmacophore, respectively.
Compound interactions amino acid residues 1equ 1i5r 3hb5 1a27 1dht
6HSer142 (donor) 3.31 3.38 3.70 3.26
Asn152 (acceptor) 2.53
a 2.45 2.56 2.97
Asn152 (donor) 2.49 2.55
Tyr155 (donor) 3.90 3.80 3.71
His221 (d donor) 3.13 3.33
p Tyr 155 6.71 3.98 3.82 4.06 4.16
Arg258 4.89
21 H Tyr155 (acceptor) 2.91 3.13 3.03 2.75 3.03
Tyr218 (donor) 3.82
His221 (donor) 2.47 2.45 2.65 2.51
Glu282 (acceptor) 2.43 2.52 2.43
p Arg258 4.34
aDistance (A ˚) between the heteroatoms for H-bonds (H) and between centroids or centroid and cation for p-interactions (p).
doi:10.1371/journal.pone.0029252.t002
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The inhibitor design concept of the present study triggered the
synthesis of compounds 6 and 21 as promising new 17b-HSD1
inhibitors by optimizing a novel, in silico identified, core scaffold
(5).
The classical medicinal chemistry approach of rigidification
was successfully applied to compound 5 and led to the discovery
of the highly potent benzothiazole 6. The introduction of the
aromatic benzothiazole freezes the position of hydroxy group in
an ideal position to establish an H-bond with H221. In addition,
this aromatic benzothiazole can undergo a cation-p interaction
with Arg258, explaining the high gain in potency of 6 compared
to 5.
In the optimization process the carbonyl bridge of 6 was varied
using several linkers with different lengths, geometries and H-
bonding properties. From the biological results as well as from the
performed in silico studies it became apparent, that the 17b-HSD1
inhibitory activity is highly influenced by the nature of the linker:
the comparison of inactive compounds showing a tetrahedral
bridge geometry (7, 8, 9, 10, 22) with the active, planar carbonyl
(6) and amide derivatives (18 and 21) led us to conclude that a flat
geometry of the linker is required for activity. The fact that the
retroamide 21 is five times more active than the amide 18 can be
explained by a steric clash observed between the carbonyl of
amide bridge and Leu149. Furthermore, the carbonyl group of 21
was found to establish an H-bond interaction with Tyr218 which is
not possible for 18.
Figure 10. Pharmacophore derived complex between 17b-HSD1 (PDB-ID: 1equ) and compound 6 (dark orange). NADP
+ (green),
interacting residues (blue), potential interacting residues (black) and ribbon rendered tertiary structure of the active site are shown.
doi:10.1371/journal.pone.0029252.g010
Figure 11. Pharmacophore derived complex between 17b-HSD1 (PDB-ID: 1equ) and compound 21 (magenta). NADP
+ (green),
interacting residues (blue), potential interacting residues (black) and ribbon rendered tertiary structure of the active site are shown.
doi:10.1371/journal.pone.0029252.g011
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that the hydroxyphenyl moieties of the two compounds do not
interact with the same area of the enzyme. In the case of
compound 6, HY5 and D4 are plausible features covered by the
hydroxyphenyl moiety. The meta-hydroxyphenyl moiety of 21,o n
the other hand, exploits HY1 and AD1. The difference in activity
between 6 and 21 is in agreement with the number of features
covered by each compound (6 versus 5).
It is striking that the newly discovered class of benzothiazole
derivatives shows structural characteristics which are similar to
those of other classes of 17b-HSD1 inhibitors: two phenolic
hydroxy-groups separated by a rather unpolar scaffold structure
[48,52,54]. The necessity for the lipophilicity of the scaffold is
reflected by the gain in potency observed with the thiourea (24:
62% inhibition at 1 mM) compared to the less lipophilic urea (23:
no inhibition at 1 mM). The analysis of the amino acid residues
which surround compound 6 in its pharmacophore binding pose
indicates that two hydrogen bonds with Asn152 and one p-p
interaction with Tyr155 are established. Recently published
docking studies suggest similar interactions for bicyclic substituted
hydroxyphenylmethanones [58]. Interestingly, there is a decrease
of activity in both compound classes when the hydroxy group is
shifted from the meta- to the para position. This similarity in SAR
supports the hypothesis that the hydroxyphenyl moieties of both
compound classes bind in the same area of the enzyme.
In order to evaluate the protein-ligand interactions, the ligands
of the different X-ray structures studied were replaced by
compounds 6 and 21 according to their pharmacophoric binding
modes and the interactions between the inhibitors 6 and 21 and
each of the crystal structures were examined. The maximum
number of interactions was observed with the crystal structure
1equ, originally containing the inhibitor equiline. The reason for
this is the residue Arg258 which protrudes into the active site in
case of 1equ. The importance of this amino acid residue was
already postulated by Alho-Richmond et al. [75], who proposed to
target it in the inhibitor design process.
The biological assays employed for the evaluation of inhibitory
potency towards 17b-HSD1 and 2 use well established conditions
[59]. In the 17b-HSD1 assay, NADH rather than NADPH is used
as cosubstrate. Substrate concentrations are adjusted to the
corresponding Km-values which are reported in the literature
[76–77] and confirmed by own experiments (data not given).
Using NADH instead of the more expensive NADPH was found
to give comparable results, as mentioned above (biological assays).
The selectivity against 17b-HSD2 should be achieved to mainly
avoid systemic effects: This enzyme is downregulated in EDD
tissues but is nevertheless present in several organs (i.e. liver, small
intestine, bones). However, it is difficult to estimate how high the
SF should be to minimize potential side effects due to the lack of
respective in vivo data. For our drug development program, an SF
of approximately 20 is considered sufficient to justify further
biological evaluation. In this study the retroamide 21 is the most
17b-HSD2 selective compound identified. It is striking that the
amide 18 shows a complete loss in selectivity against 17b-HSD2.
As no 3D-structure of this enzyme is available, an interpretation of
this result at protein level is not possible. The data indicate that the
orientation of the amide group is an important feature to gain
activity for 17b-HSD1 and selectivity against 17b-HSD2.
Affinity of the compounds to the ERs would counteract the
therapeutic concept of mainly local action, no matter whether an
agonistic or antagonistic effect is exerted. Basically, a possible
estrogenic activity may be assessed using an estrogen-sensitive cell
proliferation assay [59]. This rather laborious procedure is
envisaged for a later stage of the drug optimization process.
Earlier, we have found a good correlation between low RBA
(relative binding affinity) and lack of ER-mediated cell prolifer-
ation [59]. We therefore used a different approach to quickly
evaluate possible interference with the ERs, namely the
determination of RBA values, or, more precisely, RBA intervals:
For straightforward estimation of binding affinities, the range
within which the RBA-value of a given compound is located was
determined rather than the RBA-value itself. This approach
should not be considered as a replacement for a proliferation
assay but as a means to accelerate early stage drug design.
Compounds exhibiting RBA values of less than 0.1%
(RBA(E2)=100%) were considered selective enough for potential
in vivo application. This assumption is based on the comparison of
the compound’s binding affinity with that of E1. E1 itself is a
ligand of the ERs with an RBA of about 10% [78–79]. As E1 is
present in the diseased tissues, it competes with the inhibitor for
binding to the ERs. Due to its low RBA value (less than 0.1%), 21
should be displaced by E1 from the ER binding site and is thus
unlikely to exert an ER mediated effect in vivo. On the contrary,
compound 6 shows enhanced affinity to the ERs. This data,
however, does not allow to conclude whether the compound acts
as an agonist or an antagonist – but this is not relevant in terms of
the pursued therapeutic concept which aims at excluding systemic
effects as far as possible. Of course, an agonistic effect would be
negative for the treatment of estrogen-dependent diseases and
can obviously not be tolerated. An antagonistic mode of action,
on the other hand, will lead to systemic effects in other, healthy
steroidogenic tissues, undoing the concept of local action.
Therefore, we focused on the discovery of compounds without
low affinities to the ERs without regarding agonistic or
antagonistic action.
In the present study two new classes of 17b-HSD1 inhibitors
were identified. As no X-ray structure of the target enzyme
complexed with nonsteroidal compounds exists, a pharmacophoric
approach was followed which combines three-dimensional infor-
mation of the protein and complexed steroidal inhibitors with the
structure analysis of nonsteroidal inhibitors. Virtual screening
using the derived pharmacophore model resulted in the identifi-
cation of the fairly active hit compound 5 which was the basis for
structural modifications leading to benzothiazole-based com-
pounds with favourable biological activities. Correlating their
inhibitory potencies with the pharmacophore model gave
information about probable binding modes.
In this study, the benzothiazole 6 is the most active compound
in terms of 17b-HSD1 inhibition (IC50=44 nM). It is selective
against 17b-HSD2 (SF=24) but shows pronounced affinity to the
ERs (RBA,10% for ERa and RBA,1% for ERb). Compound
21 on the other hand showed medium inhibitory activity at the
target enzyme (IC50=243 nM) as well as selectivity not only
against 17b-HSD2 (SF=38) but also against the ERs (RBA,0.1%
for ERa and RBA,0.001% for ERb). Furthermore, 21 strongly
inhibits the intracellular formation of E2 in T47-D cells
(IC50=245 nM). Further optimizations of these first benzothia-
zole-type 17b-HSD1 inhibitors are underway in order to develop
potential candidates for in vivo application.
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25.
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Hydroxybenzothiazoles as New 17b-HSD1 Inhibitors
PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e29252[500 nM], cofactor NADH [500 mM].
b Mean values of three
determinations, standard deviation less than 10%.
c nd: not
determined.
d ni: no inhibition.
(DOC)
Table S2 Geometrical properties of the extended pharmaco-
phore model.
(DOC)
Table S3 Small in house library.
(DOC)
Table S4 Influence of bridge and hydroxy group on the
inhibition of human 17b-HSD1 and 17b-HSD2.
a Human
placenta, cytosolic fraction, substrate [
3H]E1 + E1 [500 nM],
cofactor NADH [500 mM].
b Human placenta, microsomal
fraction, substrate [
3H]E2 + E2 [500 nM], cofactor NAD
+
[1500 mM].
c Mean values of three determinations, standard
deviation less than 10%.
d Selectivity factor=IC50 (17b-HSD2)/
IC50(17b-HSD1).
(DOC)
File S1 Supporting Information.
(DOC)
Acknowledgments
We thank Prof. Rolf Hartmann for the fruitful discussion, Jannine Ludwig
for her help in performing the in vitro tests (17b-HSD1, 17b-HSD2, ERs,
cellular inhibition assay), Dr. Joseph Zapp and Dr. Stefan Boettcher for
their help in the identification of the chemical structures (NMR, LC/MS,
HPLC).
Author Contributions
Conceived and designed the experiments: AS MN. Performed the
experiments: AS. Analyzed the data: AS MN MF. Wrote the paper: AS
MN SMO EB MF.
References
1. Ferin M, Zimmering PE, Liebrman S, Vande Wiele RL (1968) Inactivation of
the biological effects of exogenous and endogenous estrogens by antibodies to
17b-Estradiol. Endocrinology 83: 565–571.
2. Jeon GH, Kim SH, Yun SC, Chae HD, Kim CH, et al. (2010) Association
between serum estradiol level and coronary artery calcification in postmeno-
pausal women. Menopause 17: 902–907.
3. Imai Y, Youn MY, Kondoh S, Nakamura T, Kouzmenko A, et al. (2009)
Estrogens maintain bone mass by regulating expression of genes controlling
function and life span in mature osteoclasts. Ann NY Acad Sci 1173: Suppl 1:
E31–E39.
4. National Cancer Institute (NCI) (2006) Understanding cancer series: estrogen
receptors/SERMs. web site: http://cancer.gov/cancertopics/understanding
cancer.
5. Liehr JG (2000) Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 21:
40–54.
6. Hall JM, Couse JF, Korach KS (2001) The multifaceted mechanisms of estradiol
and estrogen receptor signalling. J Biol Chem 276: 36869–36872.
7. Thomas DB (1984) Do hormones cause breast cancer? Cancer 53: 595–604.
8. Russo J, Fernandez SV, Russo PA, Fernbaugh R, Sheriff FS, et al. (2006)
17beta-estradiol induces transformation and tumorigenesis in human breast
epithelial cells. FASEB J 20: 1622–1634.
9. Dizerega GS, Barber DL, Hodgen GD (1980) Endometriosis: role of ovarian
steroids in initiation, maintenance, and suppression. Fertil Steril 33: 649–653.
10. Zeitoun K, Takayama K, Sasano H, Suzuki T, Moghrabi N, et al. (1998)
Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endome-
triosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab 83:
4474–4480.
11. Cavalli A, Bisi A, Bertucci C, Rosini C, Paluszcak A, et al. (2005)
Enantioselective nonsteroidal aromatase inhibitors identified through a multi-
disciplinary medicinal chemistry approach. J Med Chem 48: 7282–7289.
12. Le Borgne M, Marchand P, Duflos M, Delevoye-Seiller B, Piessard-Robert S, et
al. (1997) Synthesis and in vitro evaluation of 3-(1-azolylmethyl)-1Hindoles and
3-(1-azolyl-1-phenylmethyl)-1H-indoles as inhibitors of P450 arom. Arch Pharm
(Weinheim) 330: 141–145.
13. Jacobs C, Frotscher M, Dannhardt G, Hartmann RW (2000) 1-imidazolyl(alkyl)-
substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation
of dual inhibitors of thromboxane A(2) synthase and aromatase. J Med Chem 43:
1841–1851.
14. Janni W, Hepp P (2010) Adjuvant aromatase inhibitor therapy: outcomes and
safety. Cancer Treat Rev 36: 249–261.
15. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, et al. (2010) Effect of
anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:
10-year analysis of the ATAC trial. Lancet Oncol 11: 1135–1141.
16. Tonezzer T, Pereira CM, Filho UP, Marx A (2010) Hormone therapy/adjuvant
chemotherapy induced deleterious effects on the bone mass of breast cancer
patients and the intervention of physiotherapy: a literature review.
Eur J Gynaecol Oncol 31: 262–267.
17. Baston E, Hartmann RW (1999) N-substituted 4-(5-indolyl)benzoic acids.
Synthesis and evaluation of steroid 5alpha-reductase type I and II inhibitory
activity. Bioorg Med Chem Lett 9: 1601–1606.
18. Picard F, Baston E, Reichert W, Hartmann RW (2000) Synthesis of N-
substituted piperidine-4-(benzylidene-4-carboxylic acids) and evaluation as
inhibitors of steroid-5alpha-reductase type 1 and 2. Bioorg Med Chem 8:
1479–1487.
19. Picard F, Schulz T, Hartmann RW (2002) 5-Phenyl substituted 1-methyl-2-
pyridones and 49-substituted biphenyl-4-carboxylic acids: synthesis and evalu-
ation as inhibitors of steroid-5alpha-reductase type 1 and 2. Bioorg Med Chem
10: 437–448.
20. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M (2010) An overview
on 5alphareductase inhibitors. Steroids 75: 109–153.
21. Baston E, Palusczak A, Hartmann RW (2000) 6-Substituted 1H-quinolin-2-ones
and 2-methoxy-quinolines: synthesis and evaluation as inhibitors of steroid 5a
reductases types 1 and 2. Eur J Med Chem 35: 931–940.
22. Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M, et al. (2000) 17beta-
hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a
correlation to clinicopathological parameters. Br J Cancer 82: 518–523.
23. Speirs V, Green AR, Atkin SL (1998) Activity and gene expression of 17beta-
hydroxysteroid dehydrogenase type I in primary cultures of epithelial and
stromal cells derived from normal and tumourous human breast tissue: the role
of IL-8. J Steroid Biochem Mol Biol 67: 267–274.
24. Gunnarsson C, Ahnstro ¨m M, Kirschner K, Olsson B, Nordenskjo ¨ld B, et al.
(2003) Amplification of HSD17B1 and ERBB2 in primary breast cancer.
Oncogene 22: 34–40.
25. S ˇmuc T, Hevir N, Pucelj Ribic ˇ M, Husen B, Thole H, et al. (2009) Disturbed
estrogen and progesterone action in ovarian endometriosis. Mol Cell Endocrinol
301: 59–64.
26. Husen B, Huhtinen K, Poutanen M, Kangas L, Messinger J, et al. (2006)
Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo
in immunodeficient mice inoculated with MCF-7 cells stably expressing the
recombinant human enzyme. Mol Cell Endocrinol 248: 109–113.
27. Husen B, Huhtinen K, Saloniemi T, Messinger J, Thole HH, et al. (2006)
Human hydroxysteroid (17beta) dehydrogenase 1 expression enhances estrogen
sensitivity of MCF-7 breast cancer cell xenografts. Endocrinology 147:
5333–5339.
28. Day JM, Foster PA, Tutill HJ, Parsons MFC, Newman SP, et al. (2008)
17betahydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for
endocrine therapy of hormone-dependent breast cancer. Int J Cancer 122:
1931–1940.
29. Laplante Y, Cadot C, Fournier MA, Poirier D (2008) Estradiol and estrone C-16
derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase:
blocking of ER+ breast cancer cell proliferation induced by estrone. Bioorg
Med Chem 16: 1849–1860.
30. Kruchten P, Werth R, Bey E, Oster A, Marchais-Oberwinkler S, et al. (2009)
Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17be-
taHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells.
J Steroid Biochem Mol Biol 114: 200–206.
31. Xu K, Wetzel M, Hartmann RW, Marchais-Oberwinkler S (2011) Synthesis and
biological evaluation of spiro-d-lactones as inhibitors of 17b-hydroxysteroid
dehydrogenase type 2 (17b-HSD2). Lett Drug Disc Des 8: 406–421.
32. Wetzel M, Marchais-Oberwinkler S, Hartmann RW (2011) 17b-HSD2
inhibitors for the treatment of osteoporosis. Identification of a promising
scaffold. Bioorg Med Chem 19: 807–815.
33. Poirier D (2003) Inhibitors of 17 beta-hydroxysteroid dehydrogenases. Curr Med
Chem 10: 453–477.
34. Day JM, Tutill HJ, Purohit A, Reed MJ (2008) Design and validation of specific
inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application
in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer 15:
665–692.
Hydroxybenzothiazoles as New 17b-HSD1 Inhibitors
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e2925235. Broz ˇic P, Lanis ˇnik Riz ˇner T, Gobec S (2008) Inhibitors of 17beta-hydroxysteroid
dehydrogenase type 1. Curr Med Chem 15: 137–150.
36. Poirier D (2009) Advances in development of inhibitors of 17beta hydroxysteroid
dehydrogenases. Anticancer Agents Med Chem 9: 642–660.
37. Poirier D (2010) 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent
review. Expert Opin Ther Pat 20: 1123–1145.
38. Day JM, Tutill HJ, Purohit A (2010) 17b-Hydroxysteroid dehydrogenase
inhibitors. Minerva Endocrinol 35: 87–108.
39. Marchais-Oberwinkler S, Henn C, Mo ¨ller G, Klein T, Negri M, et al. (2011)
17b-Hydroxysteroid dehydrogenases (17b-HSDs) as therapeutic targets: protein
structures, functions, and recent progress in inhibitor development. J Steroid
Biochem Mol Biol 125: 66–82.
40. Messinger J, Hirvela ¨ L, Husen B, Kangas L, Koskimies P, et al. (2006) New
inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol
248: 192–198.
41. Allan GM, Vicker N, Lawrence HR, Tutill HJ, Day JM, et al. (2008) Novel
inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.
Bioorg Med Chem 16: 4438–4456.
42. Karkola S, Lilienkampf A, Wa ¨ha ¨la ¨ K (2008) A 3D QSAR model of 17beta-
HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying
molecular dynamics simulations and ligand-protein docking. Chem Med Chem
3: 461–472.
43. Schuster D, Nashev LG, Kirchmair J, Laggner C, Wolber G, et al. (2008)
Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by
pharmacophore-based screening of virtual compound libraries. J Med Chem 51:
4188–4199.
44. Brozic P, Kocbek P, Sova M, Kristl J, Martens S, et al. (2009) Flavonoids and
cinnamic acid derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase
type 1. Mol Cell Endocrinol 301: 229–234.
45. Lilienkampf A, Karkola S, Alho-Richmond S, Koskimies P, Johansson N, et al.
(2009) Synthesis and biological evaluation of 17beta-hydroxysteroid dehydroge-
nase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-
one core. J Med Chem 52: 6660–6671.
46. Starc ˇevic ´ S, Broz ˇic ˇ P, Turk S, Cesar J, Lanis ˇnik Riz ˇner T, et al. (2011) Synthesis
and biological evaluation of (6- and 7-phenyl) coumarin derivatives as selective
nonsteroidal inhibitors of 17b-hydroxysteroid dehydrogenase type 1. J Med
Chem 54: 248–261.
47. Starc ˇevic ´ S, Turk S, Brus B, Cesar J, Lanis ˇnik Riz ˇner T, et al. (2011) Discovery
of highly potent, nonsteroidal 17b-hydroxysteroid dehydrogenase type 1
inhibitors by virtual high-throughput screening. J Steroid Biochem Mol
Biol;doi:10.1016/j.jsbmb.2011.08.013.
48. Bey E, Marchais-Oberwinkler S, Kruchten P, Frotscher M, Werth R, et al.
(2008) Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as
potent and selective non-steroidal inhibitors of 17betahydroxysteroid dehydro-
genase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bioorg Med Chem 16: 6423–6435.
49. Bey E, Marchais-Oberwinkler S, Werth R, Negri M, Al-Soud YA, et al. (2008)
Design, synthesis, biological evaluation and pharmacokinetics of bis(hydrox-
yphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent
and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase
type 1 (17beta-HSD1). J Med Chem 51: 6725–6739.
50. Al-Soud YA, Bey E, Oster A, Marchais-Oberwinkler S, Werth R, et al. (2009)
The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of
17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2. Mol
Cell Endocrinol 301: 212–215.
51. Bey E, Marchais-Oberwinkler S, Negri M, Kruchten P, Oster A, et al. (2009)
New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes
and -benzenes: influence of additional substituents on 17beta-hydroxysteroid
dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity. J Med
Chem 52: 6724–6743.
52. Oster A, Klein T, Werth R, Kruchten P, Bey E, et al. (2010) Novel estrone
mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem 18:
3494–3505.
53. Oster A, Hinsberger S, Werth R, Marchais-Oberwinkler S, Frotscher M, et al.
(2010) Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17b-
hydroxysteroid dehydrogenase type 1 (17b-HSD1) for the treatment of estrogen-
dependent diseases. J Med Chem 53: 8176–8186.
54. Frotscher M, Ziegler E, Marchais-Oberwinkler S, Kruchten P, Neugebauer A,
et al. (2008) Design, synthesis, and biological evaluation of (hydroxyphenyl)-
naphthalene and -quinoline derivatives: potent and selective nonsteroidal
inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for
the treatment of estrogen-dependent diseases. J Med Chem 51: 2158–2169.
55. Marchais-Oberwinkler S, Kruchten P, Frotscher M, Ziegler E, Neugebauer A,
et al. (2008) Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal
inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1):
design, synthesis, biological evaluation, and pharmacokinetics. J Med Chem
51: 4685–4698.
56. Marchais-Oberwinkler S, Frotscher M, Ziegler E, Werth R, Kruchten P, et al.
(2009) Structure-activity study in the class of 6-(39-hydroxyphenyl)naphthalenes
leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid
dehydrogenase type 1 (17beta-HSD1) inhibitors. Mol Cell Endocrinol 301:
205–211.
57. Marchais-Oberwinkler S, Wetzel M, Ziegler E, Kruchten P, Werth R, et al.
(2010) New drug-like hydroxyphenylnaphthol steroidomimetics as potent and
selective 17b-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment
of estrogen-dependent diseases. J Med Chem 54: 534–547.
58. Oster A, Klein T, Henn C, Werth R, Marchais-Oberwinkler S, et al. (2011)
Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17b-hydroxy-
steroid dehydrogenase Type 1 (17b-HSD1): the role of the bicyclic moiety.
Chem Med Chem 6: 476–487.
59. Kruchten P, Werth R, Marchais-Oberwinkler S, Frotscher M, Hartmann RW
(2009) Development of a biological screening system for the evaluation of highly
active and selective 17beta-HSD1-inhibitors as potential therapeutic agents. Mol
Cell Endocrinol 301: 154–157.
60. Negri M, Recanatini M, Hartmann RW (2010) Insights in 17b-HSD1 enzyme
kinetics and ligand binding by dynamic motion investigation. PLoS ONE 5(8):
e12026. doi:10.1371/journal.pone.0012026.
61. Mazza C (1997) Human type 1 17 beta-hydroxysteroid dehydrogenase: site
directed mutagenesis and x-ray crystallography structure-function analysis.
;DOI:10.2210/pdb1a27/pdb.
62. Sawicki MW, Erman M, Puranen T, Vihko P, Ghosh D (1999) Structure of the
ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-
hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP
+. Proc Natl Acad Sci
USA 96: 840–845.
63. Han Q, Campbell RL, Gangloff A, Huang YW, Lin SX (2000) Dehydroepi-
androsterone and dihydrotestosterone recognition by human estrogenic
17betahydroxysteroid dehydrogenase. C-18/C19 steroid discrimination and
enzymeinduced strain. J Biol Chem 275: 1105–1111.
64. Qiu W, Campbell RL, Gangloff A, Dupuis P, Boivin RP, et al. (2002) A
concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase
inhibitors: estradiol-adenosine hybrids with high affinity. Faseb J 16: 1829–1831.
65. Mazumdar M, Fournier D, Zhu DW, Cadot C, Poirier D, et al. (2009) Binary
and ternary crystal structure analyses of a novel inhibitor with 17b-HSD type 1:
a lead compound for breast cancer therapy. Biochem J 424: 357–366.
66. Cabedo N, Andreu I, Ramı ´rez de Arellano MC, Chagraoui A, Serrano A, et al.
(2001) Enantioselective syntheses of dopaminergic (R)- and (S)-Benzyltetrahy-
droisoquinolines. J Med Chem 44: 1794–1801.
67. Chikashita H, Ishibaba M, Ori K, Itoh K (1988) General reactivity of 2-
lithiobenzothiazole to various electrophiles and the use as a formyl anion
equivalent in the synthesis of a-hydroxy carbonyl compounds. Bull Chem Soc
Jpn 61: 3637–3648.
68. Tang G, Nikolovska-Coleska Z, Qiu S, Yang CY, Guo J, et al. (2008)
Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins. J Med Chem 51:
717–720.
69. Nelson TD, Crouch RD (1996) Selective deprotection of silyl ethers. Synthesis 9:
1031–1069.
70. Chedekel MR, Sharp DE, Jeffery GA (1980) Synthesis of o-aminothiophenols.
Synth Commun 10: 167–173.
71. Stoner EJ, Cothron DA, Balmer MK, Roden BA (1995) Benzylation via tandem
grignard reaction - iodotrimethylsilane (TMSI) mediated reduction. Tetrahe-
dron 51: 11043–11062.
72. Kim KS, Kimball SD, Misra RN, Rawlins DB, Hunt JT, et al. (2002) Discovery
of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray
crystallographic analysis, and biological activities. J Med Chem 45: 3905–3927.
73. Jansson A, Gunnarsson C, Sta ˚l O (2006) Proliferative responses to altered
17beta-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human
breast cancer cells are dependent on endogenous expression of 17HSD type 1
and the oestradiol receptors. Endocr Relat Cancer 13: 875–884.
74. Kagechika H, Himi T, Kawachi E, Shudo K (1989) Retinobenzoic acids. 4.
Conformation of aromatic amides with retinoidal activity. Importance of trans-
amide structure for the activity. J Med Chem 32: 2292–2296.
75. Alho-Richmond S, Lilienkampf A, Wa ¨ha ¨la ¨ K (2006) Active site analysis of 17b-
hydroxysteroid dehydrogenase type 1 enzyme complexes with SPROUT. Mol
Cell Endocrinol 248: 208–213.
76. Gangloff A, Garneau A, Huang YW, Yang F, Lin SX (2001) Human oestrogenic
17beta-hydroxysteroid dehydrogenase specificity: enzyme regulation through an
NADPH-dependent substrate inhibition towards the highly specific oestrone
reduction. Biochem J 356: 269–276.
77. Puranen TJ, Kurkela RM, Lakkakorpi JT, Poutanen MH, Ita ¨ranta PV, et al.
(1999) Characterization of molecular and catalytic properties of intact and
truncated human 17beta-hydroxysteroid dehydrogenase type 2 enzymes:
intracellular localization of the wild-type enzyme in the endoplasmic reticulum.
Endocrinology 140: 3334–3341.
78. Pillon A, Boussioux A, Escande A, Aı ¨t-Aı ¨ssa S, Gomez E, et al. (2005) Binding of
estrogenic compounds to recombinant estrogen receptor-alpha: application to
environmental analysis. Environ Health Perspect 113: 278–284.
79. Zhu BT, Han G, Shim J, Wen Y, Jiang X (2006) Quantitative structure-activity
relationship of various endogenous estrogen metabolites for human estrogen
receptor alpha and beta subtypes: Insights into the structural determinants
favoring a differential subtype binding. Endocrinology 147: 4132–4150.
Hydroxybenzothiazoles as New 17b-HSD1 Inhibitors
PLoS ONE | www.plosone.org 12 January 2012 | Volume 7 | Issue 1 | e29252